EASL2025-话题@MedSci

#EASL2025#

0篇内容 | 145人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2268805, encodeId=b85d226880505, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025丨基线HBsAg、HBV RNA和HBcrAg可预测PEG IFNα治疗核苷经治慢乙肝患者48周HBsAg清除, objectType=article, longId=874527, objectId=eda88e4527cb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867576310_4754896.jpeg, objectUrl=/article/show_article.do?id=eda88e4527cb, replyNumber=0, likeNumber=4, createdTime=昨天, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=eda88e4527cb, moduleTitle=EASL2025丨基线HBsAg、HBV RNA和HBcrAg可预测PEG IFNα治疗核苷经治慢乙肝患者48周HBsAg清除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eda88e4527cb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268746, encodeId=7e0a2268e46e9, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025丨WHO 2024版指南将抗病毒应治率显著提升至61.6%, objectType=article, longId=874410, objectId=82ec8e44106d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250114/1736847778037_8538692.png, objectUrl=/article/show_article.do?id=82ec8e44106d, replyNumber=0, likeNumber=7, createdTime=2025-06-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=82ec8e44106d, moduleTitle=EASL2025丨WHO 2024版指南将抗病毒应治率显著提升至61.6%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82ec8e44106d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268404, encodeId=6ab02268404b3, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025丨新建列线图模型可预测慢乙肝患者Peg-IFNα停药后96周时的HBsAg清除, objectType=article, longId=874295, objectId=d88e8e42955f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250212/1739348837577_8538692.png, objectUrl=/article/show_article.do?id=d88e8e42955f, replyNumber=0, likeNumber=5, createdTime=2025-06-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d88e8e42955f, moduleTitle=EASL2025丨新建列线图模型可预测慢乙肝患者Peg-IFNα停药后96周时的HBsAg清除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d88e8e42955f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268262, encodeId=ec702268262e0, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025丨王福生院士：1岁以下的HBV感染婴儿可通过有限疗程抗病毒治疗获得HBsAg清除，及早获益, objectType=article, longId=862716, objectId=ab90862e1650, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240519/1716120565922_5579292.jpg, objectUrl=/article/show_article.do?id=ab90862e1650, replyNumber=0, likeNumber=5, createdTime=2025-06-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ab90862e1650, moduleTitle=EASL2025丨王福生院士：1岁以下的HBV感染婴儿可通过有限疗程抗病毒治疗获得HBsAg清除，及早获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab90862e1650)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268201, encodeId=b4a4226820189, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=413159126ed' target=_blank style='color:#2F92EE;'>#无肝纤维化#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025丨“扬帆”项目：合并MASLD显著提升无肝纤维化慢乙肝患者的抗病毒治疗应答, objectType=article, longId=874290, objectId=b66a8e42902d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240609/1717862725134_92910.png, objectUrl=/article/show_article.do?id=b66a8e42902d, replyNumber=0, likeNumber=11, createdTime=2025-06-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b66a8e42902d, moduleTitle=EASL2025丨“扬帆”项目：合并MASLD显著提升无肝纤维化慢乙肝患者的抗病毒治疗应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b66a8e42902d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2266945, encodeId=2c2e226694580, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025丨Imdusiran序贯VTP-300和低剂量Nivolumab治疗慢乙肝患者最新结果公布, objectType=article, longId=873743, objectId=6eec8e3743b4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240512/1715508384935_5579292.jpg, objectUrl=/article/show_article.do?id=6eec8e3743b4, replyNumber=0, likeNumber=13, createdTime=2025-05-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6eec8e3743b4, moduleTitle=EASL2025丨Imdusiran序贯VTP-300和低剂量Nivolumab治疗慢乙肝患者最新结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eec8e3743b4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2266946, encodeId=80e322669461a, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025丨荟萃分析：低HBsAg水平的慢乙肝患者核苷停药后的HBsAg清除率极低，仅1%左右, objectType=article, longId=874128, objectId=05e18e412834, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401030/1730265935847_8538692.jpg, objectUrl=/article/show_article.do?id=05e18e412834, replyNumber=0, likeNumber=12, createdTime=2025-05-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=05e18e412834, moduleTitle=EASL2025丨荟萃分析：低HBsAg水平的慢乙肝患者核苷停药后的HBsAg清除率极低，仅1%左右, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05e18e412834)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2266531, encodeId=e16e2266531e0, content=<a href='/topic/show?id=266a10e378e5' target=_blank style='color:#2F92EE;'>#代谢相关脂肪性肝病#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025丨MASLD显著增加HBV相关肝癌患者术后复发风险, objectType=article, longId=873742, objectId=14218e37422f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250114/1736847778037_8538692.png, objectUrl=/article/show_article.do?id=14218e37422f, replyNumber=0, likeNumber=16, createdTime=2025-05-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=14218e37422f, moduleTitle=EASL2025丨MASLD显著增加HBV相关肝癌患者术后复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14218e37422f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2266278, encodeId=108322662e88d, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025 | 乙肝新药BW-20507可显著降低慢乙肝患者HBsAg水平，停药后有反弹, objectType=article, longId=873600, objectId=2e908e360093, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250114/1736847778037_8538692.png, objectUrl=/article/show_article.do?id=2e908e360093, replyNumber=0, likeNumber=14, createdTime=2025-05-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2e908e360093, moduleTitle=EASL2025 | 乙肝新药BW-20507可显著降低慢乙肝患者HBsAg水平，停药后有反弹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e908e360093)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2266188, encodeId=63a622661883f, content=<a href='/topic/show?id=3ed881343fa' target=_blank style='color:#2F92EE;'>#肝纤维化#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL2025丨新定义的非活动性HBsAg携带人群仍有较大疾病进展风险，建议抗病毒治疗, objectType=article, longId=873398, objectId=31bf8e3398b1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240508/1715158312120_92910.png, objectUrl=/article/show_article.do?id=31bf8e3398b1, replyNumber=0, likeNumber=19, createdTime=2025-05-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=31bf8e3398b1, moduleTitle=EASL2025丨新定义的非活动性HBsAg携带人群仍有较大疾病进展风险，建议抗病毒治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31bf8e3398b1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2265173, encodeId=9f5422651e356, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=【EASL2025速递】容愈项目成果获邀口头报告：聚乙二醇干扰素α-2b治疗非活动性慢性乙型肝炎的48周HBsAg清除率超50%, objectType=article, longId=873397, objectId=aef98e339799, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250114/1736847778037_8538692.png, objectUrl=/article/show_article.do?id=aef98e339799, replyNumber=0, likeNumber=12, createdTime=2025-05-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=aef98e339799, moduleTitle=【EASL2025速递】容愈项目成果获邀口头报告：聚乙二醇干扰素α-2b治疗非活动性慢性乙型肝炎的48周HBsAg清除率超50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aef98e339799)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2264976, encodeId=c27e22649e60e, content=<a href='/topic/show?id=488344261c3' target=_blank style='color:#2F92EE;'>#失代偿期肝硬化#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=EASL热点 | 失代偿期肝硬化及其并发症管理的前沿进展, objectType=article, longId=874709, objectId=1ec28e4709b2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867576310_4754896.jpeg, objectUrl=/article/show_article.do?id=1ec28e4709b2, replyNumber=0, likeNumber=12, createdTime=2025-05-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1ec28e4709b2, moduleTitle=EASL热点 | 失代偿期肝硬化及其并发症管理的前沿进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ec28e4709b2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2264803, encodeId=1e0c226480308, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=ab90126835d7' target=_blank style='color:#2F92EE;'>#EASL2025#</a>, objectTitle=【EASL2025速递】MASLD或可促进慢乙肝患者HBV DNA转阴和HBsAg清除, objectType=article, longId=872853, objectId=e84d8e2853b4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250122/1737543636981_8538692.jpg, objectUrl=/article/show_article.do?id=e84d8e2853b4, replyNumber=0, likeNumber=18, createdTime=2025-05-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e84d8e2853b4, moduleTitle=【EASL2025速递】MASLD或可促进慢乙肝患者HBV DNA转阴和HBsAg清除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e84d8e2853b4)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

慢乙肝 EASL2025

2025-05-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #EASL2025#

EASL2025丨基线HBsAg、HBV RNA和HBcrAg可预测PEG IFNα治疗核苷经治慢乙肝患者48周HBsAg清除

昨天发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乙型肝炎# #EASL2025#

EASL2025丨WHO 2024版指南将抗病毒应治率显著提升至61.6%

2025-06-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #EASL2025#

EASL2025丨新建列线图模型可预测慢乙肝患者Peg-IFNα停药后96周时的HBsAg清除

2025-06-08发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#抗病毒治疗# #EASL2025#

EASL2025丨王福生院士：1岁以下的HBV感染婴儿可通过有限疗程抗病毒治疗获得HBsAg清除，及早获益

2025-06-07发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #无肝纤维化# #EASL2025#

EASL2025丨“扬帆”项目：合并MASLD显著提升无肝纤维化慢乙肝患者的抗病毒治疗应答

2025-06-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #EASL2025#

EASL2025丨Imdusiran序贯VTP-300和低剂量Nivolumab治疗慢乙肝患者最新结果公布

2025-05-27发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #EASL2025#

EASL2025丨荟萃分析：低HBsAg水平的慢乙肝患者核苷停药后的HBsAg清除率极低，仅1%左右

2025-05-27发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#代谢相关脂肪性肝病# #EASL2025#

EASL2025丨MASLD显著增加HBV相关肝癌患者术后复发风险

2025-05-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #EASL2025#

EASL2025 | 乙肝新药BW-20507可显著降低慢乙肝患者HBsAg水平，停药后有反弹

2025-05-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肝纤维化# #EASL2025#

EASL2025丨新定义的非活动性HBsAg携带人群仍有较大疾病进展风险，建议抗病毒治疗

2025-05-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢性乙型肝炎# #EASL2025#

【EASL2025速递】容愈项目成果获邀口头报告：聚乙二醇干扰素α-2b治疗非活动性慢性乙型肝炎的48周HBsAg清除率超50%

2025-05-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#失代偿期肝硬化# #EASL2025#

EASL热点 | 失代偿期肝硬化及其并发症管理的前沿进展

2025-05-14发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #EASL2025#

【EASL2025速递】MASLD或可促进慢乙肝患者HBV DNA转阴和HBsAg清除

2025-05-13发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务